---
title: "argenx Q2 FY26 profit rises 93% to $472 million; net sales increase 60% year-over-year to $1.52 billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293561160.md"
description: "Argenx reported a 93% year-over-year increase in Q2 FY26 profit to $472 million, with net sales rising 60% to $1.52 billion. Operating profit surged 146% to $494 million. The company expanded the U.S. label for VYVGART and VYVGART Hytrulo to all adult gMG serotypes. R&D and SG&A costs increased due to commercialization efforts and pipeline investments. Key clinical readouts for ALKIVIA and EMPASSION trials remain on track for later in 2026."
datetime: "2026-07-23T05:12:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293561160.md)
  - [en](https://longbridge.com/en/news/293561160.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293561160.md)
---

# argenx Q2 FY26 profit rises 93% to $472 million; net sales increase 60% year-over-year to $1.52 billion

-   argenx posted 2Q 2026 profit of $472 million, swinging from $245 million a year earlier; operating profit rose 146% year over year to $494 million. \* Product net sales climbed 60% year over year to $1.52 billion, rising 17% from 1Q; 1H net sales rose to $2.81 billion. \* R&D expenses increased to $486 million; SG&A costs rose to $417 million, reflecting VYVGART franchise commercialization and pipeline investment. \* Expanded the U.S. label for VYVGART and VYVGART Hytrulo to all adult gMG serotypes, including triple seronegative patients. \* Kept key readouts on track, with ALKIVIA myositis results due in 3Q26 and EMPASSION MMN data for empasiprubart expected in 4Q26. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. arGEN-X SE published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ARGX.US](https://longbridge.com/en/quote/ARGX.US.md)

## Related News & Research

- [argenx announces extraordinary shareholder meeting](https://longbridge.com/en/news/294731060.md)
- [OmniAb Q2 FY26 net loss narrows to $5.86 million; revenue more than doubled to $13.42 million](https://longbridge.com/en/news/295138809.md)
- [The AI bros are lonely](https://longbridge.com/en/news/294942232.md)
- [Covivio announces availability of 2026 half-year report](https://longbridge.com/en/news/294781698.md)
- [Marcopolo attends APIMEC 2026 investor meeting](https://longbridge.com/en/news/294988798.md)